Treatment of blood cholesterol is part of a strategy to lower atherosclerotic cardiovascular (ASCVD) risk. While use of HMG-CoA reductase inhibitors to modify cholesterol levels is the primary means of lowering the risk of an ASCVD event, residual risk remains. A new strategy being investigated is the use of cholesterol ester transfer protein (CETP) inhibitors to raise the levels of high-density lipoprotein cholesterol (HDL-C) and lower low-density lipoprotein cholesterol (LDL-C). While initial large-scale studies demonstrated no reduction of cardiovascular events, one CETP inhibitor, anacetrapib, has demonstrated a reduction in cardiovascular events in the REVEAL trial.
AliKMWonnerthAHuberKWojtaJ. Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities. Br J Pharmacol. 2012;167(6):1177-1194. doi:10.1111/j.1476-5381.2012.02081.x.
2.
StoneNJRobinsonJGLichtensteinAHet al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63(25, pt B):2889-2934.
3.
KrumholzHM. Treatment of cholesterol in 2017. JAMA. 2017;318(5):417-418. doi:10.1001/jama.2017.6753.
4.
BarterPJCaulfieldMErikssonMet al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122. doi:10.1056/NEJMoa0706628.
5.
SchwartzGGOlssonAGAbtMet al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099. doi:10.1056/NEJMoa1206797.
6.
LincoffAMNicholisSJRiesmeyerJSet al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376:1933-1942. doi:10.1056/NEJMoa1609581.
7.
The HPS3/TIMI55 -REVEAL Collaborative Group.Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017Aug29; [e-pub]. (http://dx.doi.org/10.1056/NEJMoa1706444).
8.
FerenceBAet al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA2017Aug28; [e-pub]. (http://dx.doi.org/10.1001/jama.2017.11467).
